Jump to main content
Jump to site search


Azido-galactose outperforms azido-mannose for metabolic labeling and targeting of hepatocellular carcinoma

Author affiliations

Abstract

Metabolic glycoengineering of unnatural monosaccharides provides a facile method to label cancer cells with chemical tags for glycan imaging and cancer targeting. Multiple types of monosaccharides have been utilized for metabolic cell labeling. However, the comparison of different types of monosaccharides in labeling efficiency and selectivity has not been reported. In this study, we compared N-azidoacetylgalactosamine (GalAz) and N-azidoacetylmannosamine (ManAz) for metabolic labeling of HepG2 hepatocellular carcinoma in vitro and in vivo. GalAz showed higher labeling efficiency at low concentrations, and outperformed ManAz in metabolic labeling of HepG2 tumors in vivo. GalAz mediated labeling of HepG2 tumors with azido groups significantly improved the tumor accumulation of dibenzocyclooctyne (DBCO)–Cy5 and DBCO–doxorubicin conjugate via efficient Click chemistry. This study, for the first time, uncovered the distinct labeling efficiency and selectivity of different unnatural monosaccharides in liver cancers.

Graphical abstract: Azido-galactose outperforms azido-mannose for metabolic labeling and targeting of hepatocellular carcinoma

Back to tab navigation

Supplementary files

Publication details

The article was received on 10 Jun 2019, accepted on 04 Jul 2019 and first published on 31 Jul 2019


Article type: Paper
DOI: 10.1039/C9BM00898E
Biomater. Sci., 2019, Advance Article

  •   Request permissions

    Azido-galactose outperforms azido-mannose for metabolic labeling and targeting of hepatocellular carcinoma

    H. Wang, Y. Liu, M. Xu and J. Cheng, Biomater. Sci., 2019, Advance Article , DOI: 10.1039/C9BM00898E

Search articles by author

Spotlight

Advertisements